Latest Close
$0.11
News
JUNS
Jupiter Neurosciences, Inc. News
This news view pulls recent coverage and headlines tied to JUNS.
1y Change
-$1.47 (-92.82%)
Market Cap
$5,473,436.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
none
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
IPO-Edge.com • Jul 22, 2026
Read articleBC-Most Active Stocks
Associated Press • Jul 21, 2026
Read articleJupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)
InvestorsHub • Jul 21, 2026
Read articleJupiter Neurosciences Obtains Exclusive US Rights to Potential Psychedelic Therapy for Up to $100 Million
MT Newswires • Jul 21, 2026
Read articleJupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
GlobeNewswire • Jul 21, 2026
Read articlePharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
GlobeNewswire • Jul 21, 2026
Read article